Ross A. Soo

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 772 citations

Oncology, Pathology, Bronchial Neoplasm +6

Isolation and retrieval of circulating tumor cells using centrifugal forces

Han Wei Hou, Majid Ebrahimi Warkiani, Bee Luan Khoo et al. · Scientific Reports · 2013 · 718 citations · Full text

Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis

Wen Cai Zhang, Ng Shyh‐Chang, Yang He et al. · Cell · 2012 · 666 citations · Full text

Glycine Decarboxylase Activity, Oncogenic Agent, Medicine +7

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Thoracic Oncology · 2020 · 587 citations · Full text

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5